Field Medical has announced the commencement of first-in-human trials for its FieldForce pulsed field ablation (PFA) system at Na Homolce Hospital in Prague, Czech Republic.
FieldForce, which is said to be the first and only contact force PFA system, is designed for the treatment of life-threatening ventricular arrhythmias such as ventricular tachycardia (VT) and premature ventricular contractions (PVCs).
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
As part of the Ventricular Catheter Ablation Study (VCAS), the company will enrol up to 60 patients across five global sites.
This study is pivotal in demonstrating the safety and performance of the FieldForce ablation system, which aims to overcome the limitations of current PFA and radiofrequency ablation systems.
Field Medical CEO Steven Mickelsen said: 鈥淥ur vision at Field Medical is to transform VT ablation into a widely available, one-hour outpatient procedure with improved safety outcomes.
鈥淲ith the promising early data for our VCAS study, in much the same way that PFA transformed AF, the FieldForce ablation system is optimised to transform how ventricular arrhythmias are treated, offering hope to millions of patients worldwide.鈥�
US Tariffs are shifting - will you react or anticipate?
Don鈥檛 let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataField Medical’s PFA technology offers a new solution with the first contact force PFA catheter optimised for the ventricle, potentially providing a predictable, time-efficient, and safer treatment option.
The VCAS study is a prospective safety and feasibility trial assessing the FieldForce Ablation System in patients with ventricular arrhythmias.
It is divided into two groups: VCAS-I, focusing on VT patients, and VCAS-II, targeting those with frequent PVCs.
Last year, Field Medical closed an oversubscribed seed round totalling $14m to help advance its catheter ablation platform.
Unnamed private investors led the convertible note investment, which aimed to support the company鈥檚 clinical development of the FieldBending technology.
